Lack of correlation between heparin dose and standard clinical monitoring tests in treatment with unfractionated heparin in critically ill children

Haematologica

Volumn 92, Issue 4, 2007, Pages 554-557

  Kuhle, Stefan ^a   Eulmesekian, Pablo ^a   Kavanagh, Brian ^a   Massicotte, Patricia ^b   Vegh, Patsy ^a   Lau, Alice ^a   Mitchell, Lesley G ^a,b,c  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c STOLLERY CHILDREN S HOSPITAL   (Canada)

Author keywords

Children; Monitoring; Unfractionated heparin

Indexed keywords

BLOOD CLOTTING FACTOR 10A; HEPARIN; PROTEIN ANTIBODY; ANTICOAGULANT AGENT; THROMBIN;

ACCURACY; ADOLESCENT; ANTIBODY RESPONSE; ARTICLE; BLALOCK TAUSSIG ANASTOMOSIS; BLOOD CLOTTING; CHILD; CLINICAL ARTICLE; COHORT ANALYSIS; CONTINUOUS INFUSION; CORRELATION ANALYSIS; CRITICALLY ILL PATIENT; DOSE RESPONSE; HUMAN; LOADING DRUG DOSE; LUNG EMBOLISM; NEWBORN; PARTIAL THROMBOPLASTIN TIME; PATIENT MONITORING; PROSPECTIVE STUDY; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; BLEEDING; BLOOD; BLOOD CLOTTING TEST; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; CONGENITAL HEART MALFORMATION; DRUG ANTAGONISM; DRUG MONITORING; EVALUATION; FEMALE; INFANT; INTENSIVE CARE; MALE; METHODOLOGY; POSTOPERATIVE COMPLICATION; PRESCHOOL CHILD; THROMBOPHILIA; THROMBOSIS; VEIN THROMBOSIS;

ADOLESCENT; ANTICOAGULANTS; BLOOD COAGULATION TESTS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; CRITICAL CARE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FACTOR XA; FEMALE; HEART DEFECTS, CONGENITAL; HEMORRHAGE; HEPARIN; HUMANS; INFANT; INFANT, NEWBORN; MALE; PARTIAL THROMBOPLASTIN TIME; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; PULMONARY EMBOLISM; THROMBIN; THROMBOPHILIA; THROMBOSIS; VENOUS THROMBOSIS;

EID: 34547689837     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.10696     Document Type: Article

References (15)

1. Monagle P, Chan A, Massicotte P, Chalmers E, Michelson AD. Antithrombotic therapy in children: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126 Suppl 3:645S-87S.
2. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126 Suppl 3:188S-203S.
3. Andrew M, Paes B, Milner R, Johnston M, Mitchell L, Tollefsen DM, et al. Development of the human coagulation system in the full-term infant. Blood 1987;70:165-72.
4. Andrew M, Paes B, Milner R, Johnston M, Mitchell L, Tollefsen DM, et al. Development of the human coagulation system in the healthy premature infant. Blood 1988;72:1651-7.
5. Andrew M, Vegh P, Johnston M, Bowker J, Ofosu F, Mitchell L. Maturation of the hemostatic system during childhood. Blood 1992; 80: 1998-2005.
6. Vieira A, Berry L, Ofosu F, Andrew M. Heparin sensitivity and resistance in the neonate: an explanation. Thromb Res 1991;63:85-98.
7. Schmidt B, Mitchell L, Ofosu F, Andrew M. Standard assays underestimate the concentration of heparin in neonatal plasma. J Lab Clin Med 1988;112:641-3.
8. Kuhle S, Eulmesekian P, Kavanagh B, Vegh P, Mitchell L. High Incidence of bleeding in critically ill children receiving therapeutic doses of unfractionated heparin. Haematologica 2007;92:244-7.
9. Andrew M, Marzinotto V, Massicotte P, Blanchette V, Ginsberg J, Brill-Edwards P, et al. Heparin therapy in pediatric patients: a prospective cohort study. Pediatr Res 1994;35:78-83.
10. Brandt JT, Triplett DA. Laboratory monitoring or heparin. Effect of reagents and instruments on the activated partial thromboplastin time. Am J Clin Pathol 1981;76 Suppl 4:530-7.
11. Rosborough TK. Comparison of anti-factor Xa heparin activity and activated partial thromboplastin time in 2,773 plasma samples from unfractionated heparin-treated patients. Am J Clin Pathol 1997; 108: 662-8.
12. Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001;119 Suppl 1:64S-94S.
13. Mitchell L, Vegh P, Johnson M, Andrew M. Standard heparin assays are influenced by endogenous antithrombin (AT) levels. Blood 1996; 88 Suppl 1.
14. Brill-Edwards P, Ginsberg JS, Johnston M, Hirsh J. Establishing a therapeutic range for heparin therapy. Ann Intern Med 1993;119:104-9.
15. Olson JD, Arkin CF, Brandt JT, Cunningham MT, Giles A, Koepke JA, et al. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of unfractionated heparin therapy. Arch Pathol Lab Med 1998;122:782-98.